Copyright 2003 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2003
The past 2 decades have seen tremendous improvements and refinements in pancreatic resections. The article in this issue of the ARCHIVES by Büchler and colleagues is a remarkable documentation of 617 pancreatectomies performed by a single group and echoes the results currently seen in many major centers. The pancreatoduodenectomy is now performed in a few hours at most major hospitals, with operative mortalities less than 4% and with most patients returning to normal function. Because pancreatectomy represents the only curative therapy for pancreatic adenocarcinoma, improvement in perioperative outcome is a first step toward effective treatment of this disease. However, the long-term outcome for pancreatic adenocarcinoma is still extremely poor. The actuarial 5-year survival in most major series is less than 20%, and even at major centers, there are few actual 5-year, disease-free survivors.1-3 Thus, the surgical procedure has prolonged survival but has had little effect on long-term outcome for most of the 30 000 patients each year treated for adenocarcinoma of the pancreas.
Fong Y. Changes in Morbidity After Pancreatic Resection—Invited Critique. Arch Surg. 2003;138(12):1315. doi:10.1001/archsurg.138.12.1315
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: